Medicare drug coverage

Lokelma: 2027 Medicare Part D coverage

5,350 of 5,495 Part D plans (97%) list Lokelma on their 2027 formulary, the plan's list of covered drugs (the same share as 2026). 70% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (5,172 MA-PD) and stand-alone drug plans (323 PDP).

License: a US government work, in the public domain (Public Domain Mark 1.0).

Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.

2027 compared with 2026

Lokelma is number 170 by total Medicare Part D spending in 2024 ($239 million). Plans that list it most often put it on tier 3 (a tier is the cost level a plan puts a drug on; a lower tier usually costs less). Counts use 3 RxNorm products for this name.

Lokelma Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it5,358 (97%)5,350 (97%)no change
Prior authorization (of plans that list it)237 (4%)18 (0%)-4 points
Step therapy (of plans that list it)0 (0%)0 (0%)no change
Quantity limit (of plans that list it)3,273 (61%)3,740 (70%)+9 points
Any of the three (of plans that list it)3,325 (62%)3,757 (70%)+8 points
Not listed or restricted (of all plans)3,485 (63%)3,902 (71%)+8 points

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

For pharmacies and agencies: check a whole drug list against 2027 formularies.

Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.

Formulary tier

Lokelma formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 1162 (3%)123 (2%)
Tier 212 (0%)275 (5%)
Tier 34,005 (75%)3,758 (70%)
Tier 41,179 (22%)1,194 (22%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan IDs are in both files. 475 of them (11%) added prior authorization, step therapy, or a quantity limit for Lokelma, and 50 stopped listing it.

Lokelma: plans in both 2026 and 2027
Plan by planPlans
Same plan ID in both years4,380
Listed it in 2026, not in 202750 (1%)
Listed it in 2027, not in 20265 (0%)
Moved it to a higher tier88 (2%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit475 (11%)
Added at least one of the three475 (11%)
Removed at least one of the three191 (4%)
Plan IDs new in 20271,115
2026 plan IDs not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Lokelma off the formulary or list it with prior authorization, step therapy, or a quantity limit. Montana ranks first at 93%, with 0% of its plans using prior authorization or step therapy; Hawaii ranks last at 36%. States at the same share are marked Tied and share a rank.

States from most to least restrictive for Lokelma, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Montana2793%0%+18 points
2West Virginia7091%0%+3 points
Tied 3Nevada10089%0%+8 points
Tied 3Idaho4589%0%+11 points
5Pennsylvania32488%0%+14 points
Tied 6New Jersey7485%0%+19 points
Tied 6Wyoming1385%0%+1 point
8Wisconsin9784%0%no change
Tied 9Virginia14583%0%-1 point
Tied 9Oklahoma8183%0%+18 points
Tied 11Utah5381%0%+3 points
Tied 11Kansas8481%0%+8 points
Tied 13Kentucky12380%0%+3 points
Tied 13South Carolina9180%0%+12 points
Tied 15New Mexico6879%0%+17 points
Tied 15Rhode Island2979%0%+14 points
Tied 17Texas41278%0%+15 points
Tied 17Alaska978%0%no change
Tied 19Massachusetts9277%0%+6 points
Tied 19Delaware4377%0%+8 points
21Florida54976%0%+10 points
Tied 22Iowa6473%0%+4 points
Tied 22Arkansas8673%0%+16 points
Tied 22Michigan18373%0%-9 points
Tied 22Missouri17173%0%no change
Tied 22Maine5273%0%+1 point
Tied 22North Carolina17773%0%+12 points
Tied 22Georgia15173%0%+14 points
29Indiana14072%0%no change
Tied 30District of Columbia2171%0%+3 points
Tied 30Vermont1471%0%+2 points
Tied 32Mississippi10570%0%+13 points
Tied 32New York21570%0%+7 points
34North Dakota2669%0%+2 points
Tied 35New Hampshire2568%0%-8 points
Tied 35Colorado10668%0%+2 points
Tied 37Nebraska5167%0%+12 points
Tied 37South Dakota3067%0%+7 points
39Minnesota6365%0%+19 points
40Ohio17364%0%+7 points
Tied 41Alabama11563%0%+12 points
Tied 41Connecticut5463%0%-1 point
Tied 41Louisiana12663%0%-5 points
Tied 44Illinois13362%0%+8 points
Tied 44Arizona14862%0%+3 points
46California39759%0%+10 points
47Washington11456%0%-15 points
48Tennessee15755%0%+10 points
49Oregon9254%0%+11 points
50Maryland4941%0%-7 points
51Hawaii5036%0%-6 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Lokelma off or restrict it.

Lokelma coverage by parent organization, 2027
Parent organization2027 plans ↑List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
AIDS Healthcare Foundation1100%100%100%+100 points1
Alameda Alliance for Health1100%100%100%+100 points1
AllCare Health, Inc.1100%100%100%+100 points1
AlohaCare1100%100%100%no change0
BCBS MN, MT, NE, ND, WY, Wellmark IA and SD1100%100%100%+100 points1
CareOregon, Inc.1100%100%100%no change0
Contra Costa Health Services1100%100%100%+100 points1
DLP Marquette Health Plan, LLC1100%0%0%no change0
Health Plan of San Mateo10%none list it100%no change0
IMPERIAL COUNTY LOCAL HEALTH AUTHORITY1100%100%100%+100 points1
INLAND EMPIRE HEALTH PLAN1100%100%100%+100 points1
Itasca County1100%0%0%no change0
Kern Health Systems (KHS)1100%100%100%+100 points1
Local Initiative Health Authority for LA County1100%100%100%no change0
Muscogee Creek Nation1100%100%100%new in 20270
Orange County Health Authority1100%100%100%no change0
SAN FRANCISCO HEALTH AUTHORITY1100%100%100%+100 points1
SAN JOAQUIN COUNTY HEALTH COMMISSION1100%100%100%+100 points1
SANTA BARBARA SAN LUIS OBISPO REGIONAL HEALTH AUTH1100%100%100%+100 points1
SANTA CLARA COUNTY HEALTH AUTHORITY1100%100%100%+100 points1
SANTA CRUZ MONTEREY MERCED SAN BENITO MARIPOSA MAN1100%100%100%+100 points1
Samaritan Health Services, Inc.1100%100%100%no change0
The Schroer Group, Inc.1100%100%100%+100 points1
Ventura County Medi-Cal Managed Care Commission1100%100%100%+100 points1
BayCare Health System, Inc.2100%100%100%+100 points2

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.